Power Ultrasound and the Production of Mesoscopic Particles and Aqueous Dispersions - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Power Ultrasound and the Production of Mesoscopic Particles and Aqueous Dispersions
The authors discuss advanced sonocrystallization particle-engineering techniques for manufacturing mesoscopic particles.


Pharmaceutical Technology


Dispersions, sonocrystallization, and DISCUS


Figure 1 (ALL IMAGES ARE COURTESY OF PROSONIX.)
Antisolvent precipitation is an indispensable tool for the process chemist. Crystallization can often be achieved by mixing a solution of the drug substance with an antisolvent so that, after mixing, the solution is supersaturated and crystallization occurs. The extremes of supersaturation usually cause precipitation of amorphous and ultrafine particles.


Figure 2 (ALL IMAGES ARE COURTESY OF PROSONIX.)
One can take advantage of these effects by mixing in the presence of an ultrasonic field. The two streams can be mixed either in continuous mode, using Prosonix's SonoLab ultrasonic devices, or in a recirculation process loop (see Figures 1 and 2). In the latter, the antisolvent stream is recirculated rapidly through the flow cell while the optional feed API solution is fed slowly into the flow cell (see Figure 2). Flow-rate ratios in this process often exceed 100:1 in favor of the recirculating antisolvent. High flow rates lead to rapid dispersion and crystallization of micrometer- and submicrometer-sized particles, which can then be isolated by spray drying, for example. Chemists would most often add antisolvent (e.g., the optional feed in Figure 2) to the API solution, but this reverse-antisolvent process is essential to avoid the particle growth that occurs during a normal antisolvent process. Prosonix's DISCUS is a dispersive technology that uses ultrasound.

Prosonix has produced several microcrystalline steroids using this reverse process, which is an effective means of preparing mesoscopic crystalline particles at industrial scale. The reverse process provides many options. For example, the nonsolvent–solvent system may be miscible (e.g., an ethanol solution dispersed into heptane) or immiscible (e.g., dichloromethane or toluene dispersed into water). Volatile solvents or solvent azeotropes can be continuously removed. One can also feed a melt of the API (provided its melting point is not exceptionally high) into the recirculating antisolvent. All these methods can be used for preparing aqueous nanosuspenions, often with the use of stabilizers.

Ultrasound-mediated emulsion crystallization is a novel particle-engineering technique to facilitate the formation of submicrometer- to micrometer-sized particles for improving therapeutic efficiency. This technique is beneficial for poorly water-soluble drug candidates.

In a typical process, a drug is dissolved in an organic solvent, which is immiscible with the nonsolvent of choice. Ultrasound is applied to achieve a stable emulsion. Each emulsified droplet can be subjected to heat or mass-transfer effects to achieve evaporation, cooling, or diffusion and bring about the required degree of supersaturation and crystal nucleation. The application of ultrasound assists in the dispersion and stabilization of the drug particles in the nonsolvent.

The mechanism of particle formation can be seen as a sequential process governed by applied ultrasound. After emulsification, the droplet size of the organic solution decreases because the organic solvent evaporates at high temperatures. Concurrently, the drug concentration within the droplet increases with time. When the supersaturation of drugs in the shrinking droplet is high enough, the drug, and sometimes the excipient, crystallizes.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
24%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
15%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here